Histidine

Histidine

SCHEMBL2228115

N[C@@H](CCC(=O)O)C(=O)O.N[C@@H](Cc1c[nH]cn1)C(=O)O

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.51
GRM8 O00222 2/20 0.51
GRM6 O15303 2/20 0.51
GRM7 Q14831 2/20 0.51
GRM4 Q14833 2/20 0.51
GRIA1 P42261 2/20 0.51
GRIA2 P42262 2/20 0.51
GRIA3 P42263 2/20 0.51
GRIA4 P48058 2/20 0.51
GRIN2D O15399 1/20 0.51
GRIN3B O60391 1/20 0.51
GSR P00390 1/20 0.51
GRIK1 P39086 1/20 0.51
GRM5 P41594 1/20 0.51
SLC1A3 P43003 1/20 0.51
SLC1A2 P43004 1/20 0.51
SLC1A1 P43005 1/20 0.51
GRIN1 Q05586 1/20 0.51
GRIN2A Q12879 1/20 0.51
GRIK2 Q13002 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Histidine SCHEMBL4356748 1.00 CYP1A2 (0.51) CYP1A2GRM8GRM6GRM7GRM4
Histidine SCHEMBL23306565 1.00 CYP1A2 (0.51) CYP1A2GRM8GRM6GRM7GRM4
Histidine SCHEMBL19209941 1.00 CYP1A2 (0.51) CYP1A2GRM8GRM6GRM7GRM4
Histidine SCHEMBL23291081 0.99 CYP1A2 (0.50) CYP1A2GRM8GRM6GRM7GRM4
Histidine SCHEMBL5670423 0.95 CYP1A2 (0.46) CYP1A2GRM8GRM6GRM7GRM4
Histidine SCHEMBL2730156 0.95 ALOX15 (0.49) CYP1A2GRM8GRM6GRM7GRM4
Histidine SCHEMBL4229349 0.95 CYP1A2 (0.46) CYP1A2GRM8GRM6GRM7GRM4
Histidine SCHEMBL2727906 0.95 ALOX15 (0.49) CYP1A2GRM8GRM6GRM7GRM4
Histidine SCHEMBL9389369 0.95 ALOX15 (0.49) CYP1A2GRM8GRM6GRM7GRM4
Histidine SCHEMBL17981689 0.95 GRIA1 (0.46) CYP1A2GRM8GRM6GRM7GRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210991-A1 ANTIBODY-CONTAINING FORMULATION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-07-06 US claimed
EP-4159236-A1 ANTIBODY-CONTAINING FORMULATION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-04-05 EP claimed
US-11612562-B2 Solution preparation containing stabilized antibody CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-03-28 US claimed
US-20230078678-A1 FORMULATIONS OF HUMAN ANTI-TSLP ANTIBODIES AND METHODS OF TREATING ATOPIC DERMATITIS AMGEN INC. 2023-03-16 US claimed
CN-115697404-A Antibody-containing preparation 中外制药株式会社 2023-02-03 CN claimed
EP-4103235-A1 FORMULATIONS OF HUMAN ANTI-TSLP ANTIBODIES AND METHODS OF TREATING INFLAMMATORY DISEASE Amgen Inc. (US) 2022-12-21 EP claimed
CN-115279404-A Formulation of human anti-TSLP antibodies and methods of treating inflammatory diseases 安进公司 2022-11-01 CN claimed
US-20220192179-A1 BIOMIMETIC ICE-INHIBITING MATERIAL AND CRYOPRESERVATION SOLUTION COMPRISING SAME PEKING UNIVERSITY THIRD HOSPITAL (CN) 2022-06-23 US claimed
WO-2021241720-A1 ANTIBODY-CONTAINING FORMULATION 中外製薬株式会社 2021-12-02 WO claimed
EP-3892292-A2 STABILIZED ANTIBODY-CONTAINING LIQUID FORMULATIONS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2021-10-13 EP claimed
CN-102858366-A Solution formulations containing stabilized antibodies CHUGAI PHARMACEUTICAL CO LTD 2013-01-02 CN claimed
EP-1805303-A2 MUTANT POLYMERASES FOR SEQUENCING AND GENOTYPING Li-Cor, Inc. (US) 2007-07-11 EP claimed
US-20070048748-A1 Mutant polymerases for sequencing and genotyping LI-COR, INC. (US) 2007-03-01 US claimed
WO-2006037064-A2 MUTANT POLYMERASES FOR SEQUENCING AND GENOTYPING LI-COR, INC. (US) 2006-04-06 WO claimed
US-20020049301-A1 Short peptides which selectively modulate the activity of serine/threonine kinases THE CHILDREN'S MEDICAL CENTER CORP. (US) 2002-04-25 US claimed
EP-0983346-A2 SHORT PEPTIDES WHICH SELECTIVELY MODULATE THE ACTIVITY OF SERINE/THREONINE KINASES The Children's Medical Center Corporation (US) 2000-03-08 EP claimed
WO-1998053050-A2 SHORT PEPTIDES WHICH SELECTIVELY MODULATE THE ACTIVITY OF SERINE/THREONINE KINASES THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 1998-11-26 WO claimed
EP-0210257-A4 PROTEIN WHICH IS CHARACTERISTIC OF RHEUMATOID ARTHRITIS. HURWITZ CHARLES (US) 1988-01-20 EP claimed
EP-0210257-A1 PROTEIN WHICH IS CHARACTERISTIC OF RHEUMATOID ARTHRITIS HURWITZ, Charles (US) 1987-02-04 EP claimed
WO-1986004588-A1 PROTEIN WHICH IS CHARACTERISTIC OF RHEUMATOID ARTHRITIS HURWITZ CHARLES (US) 1986-08-14 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230078678-A1 FORMULATIONS OF HUMAN ANTI-TSLP ANTIBODIES AND METHODS OF TREATING ATOPIC DERMATITIS TSLP, IL5, ORAI1 CYP1A2 4860/4885GRM8 2847/4885GRM6 1998/4885
US-20220192179-A1 BIOMIMETIC ICE-INHIBITING MATERIAL AND CRYOPRESERVATION SOLUTION COMPRISING SAME IGFBP1, IGFBP2, BCL2L1 CYP1A2 2702/4885GRM8 4667/4885GRM6 4738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.